|
|
Data from: Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial |
|
|
|
Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial. |
|
|
|
Data from: Development and Evaluation of an Online Three-Level Proton vs Photon Decision Support Prototype for Head and Neck Cancer - Comparison of Dose, Toxicity and Cost-Effectiveness |
|
|
|
Optimization of Brain and Head & Neck Radiotherapy |
|
|
|
Radiomics Digital Phantom |
|
|
|
Data from: MMP2 small immuno protein antibody uptake in xenograft tumors is associated with MMP2 activity |
|
|
|
Data from: Quantitative assessment of Zirconium-89 labeled cetuximab using PETCT imaging in patients with advanced head and neck cancer - a theragnostic approach |
|
|
|
Data from: A validated Tumor Control Probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy |
|
|
|
Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images |
|
|
|
Data from: Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – a survival model with external validation |
|
